The effect of amphetamine analogs on cleaved microtubule-associated protein-tau formation in the rat brain.
M M W Straiko, L M Coolen, F P Zemlan, G A Gudelsky
Index: Neuroscience 144(1) , 223-31, (2007)
Full Text: HTML
Abstract
The present study quantified the cleaved form of the microtubule-associated protein tau (cleaved MAP-tau, C-tau), a previously demonstrated marker of CNS toxicity, following the administration of monoamine-depleting regimens of the psychostimulant drugs amphetamine (AMPH), methamphetamine (METH), +/-3,4-methylenedioxymethamphetamine (MDMA), or para-methoxyamphetamine (PMA) in an attempt to further characterize psychostimulant-induced toxicity. A dopamine (DA)-depleting regimen of AMPH produced an increase in C-tau immunoreactivity in the striatum, while a DA- and serotonin (5-HT)-depleting regimen of METH produced an increase in the number of C-tau immunoreactive cells in the striatum and CA2/CA3 and dentate gyrus regions of the hippocampus. MDMA and PMA, two psychostimulant drugs that produce selective 5-HT depletion in the striatum, had no effect on C-tau immunoreactivity in the striatum or hippocampus. Furthermore, 5,7-dihydroxytryptamine (5,7-DHT), an established 5-HT selective neurotoxin, did not produce an increase in C-tau immunoreactivity. Dual fluorescent immunocytochemistry with antibodies to glial fibrillary acidic protein (GFAP) and C-tau indicated that C-tau immunoreactivity was present in astrocytes, not neurons, suggesting that increased C-tau may be an alternative indicator of reactive gliosis. The present results are consistent with previous findings that the DA-depleting psychostimulants AMPH and METH produce reactive gliosis whereas the 5-HT-depleting drugs MDMA and PMA, as well as the known 5-HT selective neurotoxin 5,7-DHT, do not produce an appreciable glial response.
Related Compounds
Related Articles:
2009-05-02
[Toxicology 259(1-2) , 61-8, (2009)]
2007-04-25
[Neuroscience 146(1) , 321-9, (2007)]
2005-04-11
[Brain Res. 1041(1) , 48-55, (2005)]
2010-06-01
[Analyst 135(6) , 1449-55, (2010)]
2006-09-28
[Eur. J. Pharmacol. 546(1-3) , 74-81, (2006)]